Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Polyneurophathy
Status:
Withdrawn
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
See updated study design under NCT04882735. Phase 3 efficacy and safety of AG10 compared with
placebo in subjects with symptomatic Transthyretin Amyloid Polyneuropathy (ATTR-PN)
Phase:
Phase 3
Details
Lead Sponsor:
Eidos Therapeutics Eidos Therapeutics, a BridgeBio company